Compare

Geron/$GERN

1D1W1M3M6MYTD1Y5YMAX

About Geron

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Ticker
$GERN
Sector
Health
Primary listing
NASDAQ
Employees
258

Geron Metrics

BasicAdvanced
$588M
-
-$0.08
0.61
-

What the Analysts think about Geron

Analyst ratings (Buy, Hold, Sell) for Geron stock.
Analyst projections of the future price of Geron stock.

Bulls say / Bears say

RYTELO’s launch is still growing: Q3 2026 revenue rose 27% year on year to $60.1 million, while demand increased 10% from the previous quarter. Geron also reported more prescribing accounts, reaching about 1,700. (GlobeNewswire)
A staged European launch could add patients and revenue beyond the US: RYTELO is expected to become available in Germany by year-end 2026, with France planned for 2027. The gated approach lets Geron expand access without committing to a large upfront build-out. (GlobeNewswire)
Geron’s finances showed signs of improvement in Q3: it reported $1.4 million of net income, compared with a loss a year earlier, and cash and marketable securities rose to about $339 million. It also lowered its 2026 operating-expense guidance to $220 million–$230 million. (SEC)
The Phase 3 IMpactMF trial was stopped after an independent committee judged it unlikely to meet its overall-survival goal. This removes a major potential route to expanding RYTELO into relapsed or refractory myelofibrosis. (GlobeNewswire, SEC)
Geron is now more dependent on RYTELO succeeding in lower-risk MDS, leaving little product diversification if sales disappoint. The company itself identified this greater reliance after discontinuing the myelofibrosis trial. (SEC)
The European opportunity may be slower or more costly to capture than hoped: Geron says it lacks experience commercialising medicines outside the US and will rely on third parties, while country-by-country pricing and reimbursement remain hurdles. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

Geron Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Geron Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.